pancreatic cancer cell lines miapaca 2 (ATCC)
Structured Review

Pancreatic Cancer Cell Lines Miapaca 2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 4593 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/miapaca+2+cells/MIA+PaCa-2/pmc13763989-277-1-6
Average 99 stars, based on 4593 article reviews
Images
1) Product Images from "Activity of Fluoro-Substituted 3,5-Di[( E )-Benzylidene]piperidin-4-Ones with N -Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells"
Article Title: Activity of Fluoro-Substituted 3,5-Di[( E )-Benzylidene]piperidin-4-Ones with N -Arylsulfonyl Appendages Against KRAS-Mutant Pancreatic Ductal Adenocarcinoma Cells
Journal: International Journal of Molecular Sciences
doi: 10.3390/ijms272110013
Figure Legend Snippet: Antiproliferative activity of test compounds against MiaPaCa-2 and S2-007 pancreatic cancer cells, expressed as IC 50 (µM) 1 after 48 h of treatment, as determined by a hexosaminidase assay. 5-Fluorouracil (5-FU) served as a positive control.
Techniques Used: Activity Assay, Hexosaminidase Assay, Positive Control
Figure Legend Snippet: Dose- and time-dependent antiproliferative activity of 4b (A4, panel ( A )), 4a (A5, panel ( B )), and 3a (A19, panel ( C )) against MiaPaCa-2 and S2-007 PDAC cells. Cells were treated with 0–2.5 µM of each compound for 24–72 h, and proliferation was measured by hexosaminidase assay and expressed as a percentage of untreated control. Data are presented as mean ± SD of three independent experiments.
Techniques Used: Activity Assay, Hexosaminidase Assay, Control
Figure Legend Snippet: Time-dependent antiproliferative activity of 3a against KRAS-mutant PDAC cells (MiaPaCa-2, S2-007, Panc-1) and the human leukemia cell lines Jurkat and THP-1 cells, expressed as IC 50 (µM) 1 , as determined by a hexosaminidase assay (PDAC lines) or CCK-8 assay (Jurkat and THP-1 cells).
Techniques Used: Activity Assay, Hexosaminidase Assay, CCK-8 Assay
Figure Legend Snippet: Compound 3a induces apoptosis in PDAC cells. ( A ) Representative Annexin V-FITC/PI flow cytometry dot plots of MiaPaCa-2 (top) and Panc-1 (bottom) cells treated with vehicle (Ctrl) or 3a (A19) at IC 50 (260 nM MiaPaCa-2; 560 nM Panc-1) for 48 h. Quadrants show live (Annexin V − /PI − ), early apoptotic (Annexin V + /PI − ), late apoptotic (Annexin V + /PI + ), and necrotic (Annexin V − /PI + ) cells. ( B ) Quantification of the percentage of cells in each quadrant for MiaPaCa-2 (left) and Panc-1 (right) cells. Dots represent independent experiments ( n = 3); p -values were determined by an unpaired two-tailed Student t -test for each quadrant. ( C ) Caspase-3/7 activity in MiaPaCa-2 and S2-007 cells after 48 h of treatment with 3a (A19) at ½ IC 50 (130 nM MiaPaCa-2; 110 nM S2-007) or IC 50 (260 nM MiaPaCa-2; 220 nM S2-007), expressed relative to untreated control (Ctrl, 0 nM). Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by one-way ANOVA with Bonferroni–Šídák correction for multiple comparisons versus control. ( D ) Effect of 3a (A19) on apoptosis-related protein expression in MiaPaCa-2 and S2-007 cells. Western blots show reduced Bcl-2, Bcl-Xl, and cyclin D1 levels in cells treated with 3a at its IC 50 concentration (+) for 24 h or 48 h compared with vehicle (−), while Bax expression remained unchanged. GAPDH was used as a loading control. Densitometric quantification from three independent experiments is shown in .
Techniques Used: Flow Cytometry, Two Tailed Test, Activity Assay, Control, Expressing, Western Blot, Concentration Assay
Figure Legend Snippet: Compound 3a inhibits primary and secondary spheroid formation in PDAC cells. ( A ) Representative brightfield images of primary MiaPaCa-2 (top) and S2-007 (bottom) spheroids after 7 days in the absence (Ctrl) or presence of 3a (A19) at its IC 50 concentration. ( B ) Quantification of primary spheroid number per well for MiaPaCa-2 and S2-007 cells. ( C ) Representative brightfield images of secondary MiaPaCa-2 (top) and S2-007 (bottom) spheroids formed after primary spheroids from control and 3a -treated wells were dissociated and re-plated in drug-free spheroid medium for 5 days. ( D ) Quantification of secondary spheroid number per well for MiaPaCa-2 and S2-007 cells. Data in ( B ) and ( D ) are shown as box-and-whisker plots (median, interquartile range, and min–max) with individual data points; p -values were determined by unpaired two-tailed Student’s t -test. Dots represent individual wells ( n = 9 per group, 3 wells from each of 3 independent experiments).
Techniques Used: Brightfield, Spheroids, Concentration Assay, Control, Whisker Assay, Two Tailed Test
Figure Legend Snippet: Compound 3a inhibited colony formation in PDAC cells. ( A ) Representative crystal-violet-stained wells of MiaPaCa-2 (top) and S2-007 (bottom) cells 10–12 days after a 48 h treatment with 0, ½ IC 50 (0.5X), or IC 50 (1X) concentrations of 3a (A19) followed by drug-free recovery. ( B ) Quantification of colony number for MiaPaCa-2 and S2-007 cells under the same conditions. Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by one-way ANOVA with Bonferroni–Šídák correction for multiple comparisons versus untreated control.
Techniques Used: Colony Assay, Staining, Control
Figure Legend Snippet: Compound 3a inhibited STAT3 phosphorylation (Tyr705) in PDAC cells. ( A ) Western blots of p-STAT3 in MiaPaCa-2 and S2-007 cells treated with vehicle or 3a (A19) at its IC 50 concentration for 24 h or 48 h; GAPDH served as a loading control. ( B ) Densitometric quantification of p-STAT3 (Tyr705) normalized to total STAT3, relative to the respective untreated control, for each cell line and time point. Data are presented as mean ± SD; dots represent independent experiments ( n = 3). p -values were determined by an unpaired two-tailed Student t -test versus the time-matched vehicle control.
Techniques Used: Phospho-proteomics, Western Blot, Concentration Assay, Control, Two Tailed Test
Figure Legend Snippet: Cellular thermal shift assay (CETSA) showing that 3a binds STAT3. ( A ) Representative Western blots of soluble STAT3 in MiaPaCa-2 cell lysates incubated with vehicle (DMSO) or 3a (A19) at 20 µM for 4 h, then heated at the indicated temperatures (44–68 °C) for 3 min. ( B ) Melting curves of soluble STAT3, quantified by densitometry and normalized to the 44 °C sample of each group. Curves were fitted by nonlinear (Boltzmann sigmoidal) regression. Derivative 3a raised the melting temperature (T m ) of STAT3 from 56.3 °C (vehicle) to 62.6 °C (ΔT m = +6.3 °C), indicating thermal stabilization of STAT3 by direct ligand binding. Data are presented as mean ± SD ( n = 3). p -values above individual temperatures compare vehicle with 3a at each temperature; the overall curve comparison (extra sum-of-squares F-test) gave p < 0.0001.
Techniques Used: Thermal Shift Assay, Western Blot, Incubation, Ligand Binding Assay, Comparison
Related Articles
Incubator:Article Title: Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring Article Snippet: .. Modification:Article Title: Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring Article Snippet: .. Article Title: Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance Article Snippet: .. Concentration Assay:Article Title: Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring Article Snippet: .. Cell Culture:Article Title: Enhanced efficacy of combination of gemcitabine and phosphatidylserine-targeted nanovesicles against pancreatic cancer Article Snippet: .. Article Title: Targeting tumor antioxidant pathways with novel GSTP1/M2 inhibitors for cancer treatment Article Snippet: .. MDA-MB-231 cells (ATCC) grown in DMEM supplemented with 10% FBS and penicillin-streptomycin (50 μg/mL), Article Title: Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance Article Snippet: .. Multiple Displacement Amplification:Article Title: Targeting tumor antioxidant pathways with novel GSTP1/M2 inhibitors for cancer treatment Article Snippet: .. MDA-MB-231 cells (ATCC) grown in DMEM supplemented with 10% FBS and penicillin-streptomycin (50 μg/mL), |



